KR960031602A - 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조 방법 - Google Patents

유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조 방법 Download PDF

Info

Publication number
KR960031602A
KR960031602A KR1019950002751A KR19950002751A KR960031602A KR 960031602 A KR960031602 A KR 960031602A KR 1019950002751 A KR1019950002751 A KR 1019950002751A KR 19950002751 A KR19950002751 A KR 19950002751A KR 960031602 A KR960031602 A KR 960031602A
Authority
KR
South Korea
Prior art keywords
glycine
insulin precursor
insulin
proline
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019950002751A
Other languages
English (en)
Other versions
KR0150565B1 (ko
Inventor
신항철
장승구
김대영
Original Assignee
김정재
주식회사 한일합섬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김정재, 주식회사 한일합섬 filed Critical 김정재
Priority to KR1019950002751A priority Critical patent/KR0150565B1/ko
Priority to US08/600,783 priority patent/US5962267A/en
Priority to GB9602998A priority patent/GB2298206B/en
Priority to JP8027835A priority patent/JPH08333395A/ja
Priority to DE19605657A priority patent/DE19605657B4/de
Priority to FR9601888A priority patent/FR2730495B1/fr
Publication of KR960031602A publication Critical patent/KR960031602A/ko
Application granted granted Critical
Publication of KR0150565B1 publication Critical patent/KR0150565B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 종양괴사인자 알파의 DNA단편을 융합파트너로 벡터에 삽입하고, 하기 일반식을 지닌 일슐린 전구체를 코우딩하는 DNA를 벡터에 삽입하여 형질전환시킨 벡터를, 미생물 숙주에 도입하여 배양후, 배양물을 분리, 정제함을 특징으로 하는 하기 일반식을 지닌 인슐린 전구체의 제조방법에 관한 것이다.
B사슬-X-A사슬 상기식에서 X는 다음의 식을 갖는다. A-A-B-C-D-En-A-A A : 아르지닌 또는 라이신, B : 불특정 아미노산, C : 프롤린, D : 글라이신, 아르지닌 또는 라이신, E : 불특정 아미노산 서열, n은 0부터 5이다.

Description

유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 플라스미드 pT7-T1 및 pT7-T2의 조립에 관한 개요를 나타낸 것이다,
제2도는 플라스미드 pT1-hPI 및 pT2-hPl의 조립에 관한 개요를 나타낸 것이다,
제3도는 플라스미드 pT1-M1PI, pT1-M2PI, pT1-M3PI 및 pT1-M4PI의 조립에 관한 개요를 나타낸 것이다.

Claims (15)

  1. 아래의 일반식의 펩타이드 서열을 갖는 일슐린 전구체 B사슬-X-A사슬 상기식에서 X는 다음의 식을 갖는다. A-A-B-C-D-En-A-A A : 아르지닌 또는 라이신, B : 불특정 아미노산, C : 프롤린, D : 글라이신, 아르지닌 또는 라이신, E : 불특정 아미노산 서열, n은 0부터 5이다.
  2. 제1항에 있어서, B가 알라닌, 타이로신, 히스티딘, 글라이신 중의 하나의 아미노산이고, n이 2이고 E가 아스파라진산, 발린 또는 아르지닌, 글라이신임을 특징으로 하는 일슐린 전구체.
  3. 제2항에 있어서, B,C,D가 각각 알라닌, 프롤린, 글라이신이고, E가 아스파라진산, 발린임을 특징으로 하는 일슐린 전구체.
  4. 제2항에 있어서, B,C,D가 각각 타이로신, 프롤린, 글라이신이고, E가 아스파라진산, 발린임을 특징으로 하는 일슐린 전구체.
  5. 제2항에 있어서, B,C,D가 각각 히스티딘, 프롤린, 글라이신이고, E가 아스파라진산, 발린임을 특징으로 하는 일슐린 전구체.
  6. 제1항에 있어서, B,C,D가 각각 글라이신, 프롤린, 글라이신이고, n이 0임을 특징으로 하는 인슐린 전구체.
  7. 제2항에 있어서, B,C,D가 각각 글라이신, 프롤린, 아르지닌이고, E가 아르지닌, 글라이신임을 특징으로 하는 인슐린 전구체.
  8. 제1항 내지 제7항 중 어느 한 항의 인슐린 전구체를 코우딩하는 DNA 염기서열.
  9. 제8항의 염기서열 삽입시킨 벡터.
  10. 제9항의 벡터에 의해 형질 전환된 미생물.
  11. 제10항에 있어서, pT1-M1PI로 형질 전환된 대잘균 BL21(DE 3)(기탁번호 : KCCM-10059)
  12. 제10항에 있어서, pT2-M2PI로 형질 전환된 대잘균 BL21(DE 3)(기탁번호 : KCCM-10060)
  13. 종양괴사인자 알파의 DNA단편을 융합파트너로 벡터에 삽입하고, 제1항의 일반식을 지닌 인슐린 전구체를 코우딩하는 DNA를 벡터에 삽입하여 형질전환시킨 벡터를, 미생물 숙주에 도입하여 배양후, 배양물을 분리, 정제함을 특징으로 하는 제1항의 일반식을 지닌 인슐린 전구체의 제조방법.
  14. 제13항에서 만들어진 일슐린 전구체로부터 리폴딩, 단백질효소 가수분해등의 공정을 거쳐 인체 인슐린을 제조하는 방법.
  15. 제14항에서 만들어진 인체 일슐린 및 약학적으로 허용되는 담체를 함유하는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950002751A 1995-02-15 1995-02-15 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법 Expired - Fee Related KR0150565B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1019950002751A KR0150565B1 (ko) 1995-02-15 1995-02-15 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
US08/600,783 US5962267A (en) 1995-02-15 1996-02-13 Proinsulin derivative and process for producing human insulin
GB9602998A GB2298206B (en) 1995-02-15 1996-02-14 Proinsulin derivative and process for producing human insulin
JP8027835A JPH08333395A (ja) 1995-02-15 1996-02-15 ヒトプロインスリン誘導体およびヒトインスリンの製造方法
DE19605657A DE19605657B4 (de) 1995-02-15 1996-02-15 Menschliches Proinsulinderivat, Kodierende DNA, DNA enthaltender Expressionsvektor, mit diesem transformierter Mikroorganismus und Verwendung dieses menschlichen Proinsulinderivats
FR9601888A FR2730495B1 (fr) 1995-02-15 1996-02-15 Derive de proinsuline et procede pour la production d'insuline humaine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950002751A KR0150565B1 (ko) 1995-02-15 1995-02-15 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법

Publications (2)

Publication Number Publication Date
KR960031602A true KR960031602A (ko) 1996-09-17
KR0150565B1 KR0150565B1 (ko) 1998-08-17

Family

ID=19408146

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950002751A Expired - Fee Related KR0150565B1 (ko) 1995-02-15 1995-02-15 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법

Country Status (6)

Country Link
US (1) US5962267A (ko)
JP (1) JPH08333395A (ko)
KR (1) KR0150565B1 (ko)
DE (1) DE19605657B4 (ko)
FR (1) FR2730495B1 (ko)
GB (1) GB2298206B (ko)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118127A0 (en) * 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
JP3406244B2 (ja) * 1999-04-30 2003-05-12 伊藤ハム株式会社 新規な融合蛋白質からの組み換えインスリンの製造方法
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6521738B2 (en) * 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
RU2283846C2 (ru) * 1999-12-29 2006-09-20 Ново Нордиск А/С Предшественник инсулина, способ его получения и применение
US6777207B2 (en) * 1999-12-29 2004-08-17 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
US7378390B2 (en) * 1999-12-29 2008-05-27 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
JP4795599B2 (ja) * 1999-12-29 2011-10-19 ノボ ノルディスク アクティーゼルスカブ 酵母において改良された発酵収率を有するインスリン前駆体及びインスリン前駆体類似体の製造方法
KR100449454B1 (ko) * 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
DE60104069T2 (de) * 2000-10-02 2005-08-25 Yonsei University Einkettige Insulinanaloge
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2002079251A2 (en) * 2001-04-02 2002-10-10 Novo Nordisk A/S Method for making human insulin precursors
EP1377608B1 (en) * 2001-04-02 2009-09-16 Novo Nordisk A/S Insulin precursors and a process for their preparation
US7105314B2 (en) * 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP2005501530A (ja) * 2001-06-08 2005-01-20 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 体細胞株におけるヒトインスリンのグルコース−調節された産生のために有用な核酸構築物
US20030040601A1 (en) * 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
US7790677B2 (en) * 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
CA2703830A1 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
ES2543705T3 (es) 2009-06-26 2015-08-21 Novo Nordisk A/S Preparación que contiene insulina, nicotinamida y arginina
WO2012115637A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Aspart proinsulin compositions and methods of producing aspart insulin analogs
WO2012115638A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Glargine proinsulin compositions and methods of producing glargine insulin analogs therefrom
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
WO2012115640A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Liquid insulin- containing compositions and methods of making the same
WO2013059213A1 (en) 2011-10-18 2013-04-25 Amidebio, Llc Chemically and thermodynamically stable insulin analogues and improved methods for their production
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
US9163073B2 (en) 2013-04-17 2015-10-20 Amidebio, Llc Chemically and thermodynamically stable insulin analogues and improved methods for their production
CN104592381A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种利拉鲁肽中间体多肽的制备方法
JP2018531007A (ja) * 2015-09-24 2018-10-25 ハンミ ファーマシューティカル カンパニー リミテッド インスリンの製造方法
AU2020418207A1 (en) 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
BR112022013009A2 (pt) 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) * 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
CA1204682A (en) * 1981-06-19 1986-05-20 Saran A. Narang Adaptors, and synthesis and cloning of proinsulin genes
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
DK129385A (da) * 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DK336188D0 (da) * 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
DE3919852A1 (de) * 1988-06-23 1989-12-28 Hoechst Ag Mini-proinsulin, seine herstellung und verwendung
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
CA2165781C (en) * 1993-06-21 2007-02-13 Tim Breece Process for producing relaxin
WO1995016708A1 (en) * 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds

Also Published As

Publication number Publication date
GB2298206A (en) 1996-08-28
GB2298206B (en) 1998-12-09
FR2730495A1 (fr) 1996-08-14
US5962267A (en) 1999-10-05
GB9602998D0 (en) 1996-04-10
DE19605657A1 (de) 1996-08-22
DE19605657B4 (de) 2005-12-22
KR0150565B1 (ko) 1998-08-17
JPH08333395A (ja) 1996-12-17
FR2730495B1 (fr) 2001-11-23

Similar Documents

Publication Publication Date Title
RU2339646C2 (ru) Гибридная и тандемная экспрессия белков нейссерий
FI80906C (fi) Foerfarande foer extraktion av intakt rekombinant-human-immuninterferonprotein.
DK1013765T3 (da) Fremgangsmåde til fremstilling af L-aminosyrer
ES2044841T3 (es) Procedimiento de preparacion de peptidos sinteticos con actividad de interleuquin 1 humana.
FI943591A7 (fi) Synteettinen hemofilus-influenssa yhdistelmärokote
KR880010130A (ko) 폴리 펩티드, dna 및 그의 용도
KR910016343A (ko) 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
BG101408A (bg) Аналози на кератиноцитния растежен фактор
KR940019726A (ko) 종양괴사인자- 알파 뮤테인
KR870000428A (ko) 인체혈청 알부민의 제조방법
ATE235916T1 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
KR880000589A (ko) 플라비 비루스 항원
Browning et al. Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
PT635025E (pt) Processo para preparar proteinas modificadas
DK0652903T3 (da) Nyt humant rekombinant gammainterferon
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
CA2521038A1 (en) Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production
ATE290088T1 (de) Verfahren zur spaltung eines chimeren proteins mittels eines 'processing'-enzyms
AU629430B2 (en) Bacterial collagenase gene
AU603545B2 (en) Media for increased yield of protein free of N-terminal methionine from recombinant escherichia coli
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20060613

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20070616

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20070616

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000